Earlier, the idea of co-targeting Mcl-1 and Noxa in MCL cells was proposed by combining CDK inhibitor dinaciclib and fatty acid synthase (FASN) inhibitors, e.g., orlistat [49]. This evidence concerns the gene MCL1 and mantle cell lymphoma.